Medical Device & Healthcare Industry Trends — 2026-07-11
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
As the Korean medical device industry gains global competitiveness through expanded rapid approval systems and streamlined digital health regulations, the U.S. FDA’s move to ease regulations on wearable and AI devices is creating new opportunities for Korean firms. With the global AI medical device market projected to reach $84.8 billion by 2033, international competition among Korean digital therapeutics and AI diagnostic startups is intensifying.
Medical Device & Healthcare Industry Trends — 2026-07-11
Today's Top 5 Headlines
- FDA Eases Regulations on Wearables/AI: The U.S. FDA released guidelines exempting low-risk wearables and AI health software from oversight.
- Global AI Medical Device Market Growth: Expected to grow from $29 billion in 2025 to $84.8 billion by 2033, a CAGR of 12.9%.
- CMS Establishes New AI Office: The U.S. Centers for Medicare & Medicaid Services (CMS) is building a framework to support billing for AI wearables and remote patient monitoring.
- First LLM-based Medical Device Approved by FDA: UpDoc received 510(k) clearance for a device powered by a large language model.
- 45 MFDS Innovative Device Designations in Korea: The number of products using AI and big data designated as innovative rose by 50% in 2025, accelerating the pace of innovation.
Key Corporate Trends
Expanded MFDS Innovative Medical Device Designations
- What Happened: The Ministry of Food and Drug Safety (MFDS) designated 45 products as innovative medical devices in 2025, a 50% increase year-over-year.
- Numbers: 45 products designated, +50% increase; higher proportion of AI and big data-driven products.
- Implications: This signals that the Korean medical device industry is rapidly adopting advanced technology and that the ecosystem for next-generation device development is maturing. Active support from the MFDS is expected to boost the global competitiveness of domestic innovators.
Launch of Korea's 'Market Immediate Entry' System
- What Happened: The Ministry of Health and Welfare and the MFDS officially launched the "Fast-Track" market access system for innovative medical technologies on January 26, following the completion of the pilot phase.
- Numbers: New fast-track approval path; goal of achieving medical device approval within 240 days.
- Implications: Korea is building a "world-class, high-speed approval system" to compete with the FDA and EU. This creates an environment where major domestic firms like Samsung Medison, Osstem Implant, and Vieworks can quickly commercialize and launch innovative products globally.
FDA Announces Policy to Ease Wearable/AI Regulations
- What Happened: The U.S. FDA released guidelines providing regulatory exemptions for low-risk wearable health functions and AI-based clinical decision support tools.
- Numbers: Non-medical wearable data excluded from regulations; FDA approval exempted for low-risk clinical decision support tools.
- Implications: The global market is expanding rapidly, providing significant opportunities for Korean tech giants like Samsung and LG. Additionally, Korean AI diagnostic startups like Lunit and Vuno need to adapt their FDA 510(k) strategies accordingly.
Global AI Medical Device Market to Reach $84.8 Billion by 2033
- What Happened: DataM Intelligence projects the global AI medical device market will grow from $29 billion in 2025 to $84.8 billion by 2033.
- Numbers: CAGR of 12.9%; market size expected to triple over eight years.
- Implications: As AI-based diagnostics, monitoring, and surgical workflows scale clinically, demand for global expansion among Korean digital health firms is surging. The MFDS’s rapid approval system is becoming a vital element in securing this opportunity.
MFDS, Policy, and Regulation
MFDS Pushing to Revise Digital Medical Device Classification
- Content: The MFDS is working on revisions to reclassify digital medical devices and is refining review guidelines for products using AI and machine learning.
- Target: Digital therapeutics (DTx), Software as a Medical Device (SaMD), AI diagnostic devices, etc.
- Implementation: Detailed guidelines expected in the first half of 2026.
- Industry Impact: Clarified regulations are expected to improve predictability for domestic startups, specifically regarding clinical trial design and data requirements, shortening development timelines.
Elimination of 'Suspension Grace Period' for GMP Violations
- Content: The MFDS decided to stop granting grace periods for sales suspensions when periodic GMP inspection violations are discovered before the expiration date.
- Target: All medical device manufacturers, especially those using contract manufacturing for key processes.
- Implementation: Effective March 2026.
- Industry Impact: This significantly increases GMP compliance burdens, requiring stricter quality control for overseas contract manufacturing. Preparations are essential, especially for in-vitro diagnostic device manufacturers.
Discussions on Separating Manufacturing vs. Product Licensing
- Content: The industry is requesting improvements to the separation between facility manufacturing licenses and individual product licenses; the MFDS is reviewing relevant regulatory amendments.
- Target: Contract manufacturers and companies producing multiple product lines.
- Implementation: Regulatory improvement plan expected in the second half of the year.
- Industry Impact: If implemented, this could lower barriers for small and medium-sized enterprises and improve manufacturing efficiency by establishing clear standards for outsourced processes.
Digital Health & AI Medicine
-
FDA Approval of UpDoc (First LLM-based Device): An AI agent with an LLM received 510(k) clearance, setting a new paradigm for clinical decision support and providing a benchmark regulatory path for Korean developers.
-
U.S. CMS Establishes New AI Office: The CMS created a dedicated team for AI wearables and Remote Patient Monitoring (RPM) reimbursement, accelerating policies for digital health services. This offers a clear path for Korean telemedicine firms to negotiate reimbursements when entering the U.S. market.
-
Global Wearable Market Moves Toward Medicalization: Samsung, LG, and Apple are seeking FDA approval and clinical validation for wearable ECG, blood glucose monitoring, and sleep tracking. Korean companies must also align their wearable medicalization strategies.
Global MedTech Context
-
Spread of FDA Wearable/AI Deregulation: The U.S. move to exempt low-risk wellness features and non-medical AI tools provides a regulatory advantage for global expansions by companies like Samsung Medison and LG Healthcare.
-
AI Market Growth Opportunities: With the global AI medical device market growing at a 12.9% CAGR, urgent action is needed for the FDA 510(k) and CE Mark strategies of AI diagnostic startups like Lunit, Vuno, and Medipana.
-
Exclusion of Non-Medical Wearables from Regulation: The FDA Commissioner’s clarification that non-medical wearable data is exempt from regulation frees Korean firms to market consumer health devices globally with less regulatory risk.
Investment, M&A, and Listing Trends
Currently, there is limited information on medical device/healthcare investment deals within the last 24 hours.
Today's Insight
The MFDS’s goal of "approval within 240 days" and the U.S. FDA’s easing of wearable/AI regulations are moving in complementary directions. The MFDS is speeding up regulation, while the FDA is reducing regulation for low-risk products. This offers a dual opportunity for Korean companies: securing competitiveness at home through fast approvals and easier global entry in the U.S. It is the perfect time for firms like Samsung Medison, Lunit, and Vuno to move quickly to capture the 12.9% annual growth in the digital health and AI market.
This Week’s Checkpoints
- Monitor the announcement date for MFDS digital medical device guidelines (expected H1).
- Review detailed criteria for FDA wearable clinical trial exemptions.
- Analyze discrepancies between reports on the global AI medical device market.
- Track U.S. 510(k) application status for Korean medical device companies.
Reader Action Items
- Manufacturers: Re-check MFDS periodic GMP compliance checklists and strengthen quality oversight for contract manufacturers.
- Digital Health Startups: Study the UpDoc case and FDA 510(k) guidelines for LLM-based medical devices.
- Global Expansion Firms: Verify FDA wearable regulatory exemption items and refine marketing strategies and clinical trial designs accordingly.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
